MDM2-Based Proteolysis-Targeting Chimeras (PROTACs): An Innovative Drug Strategy for Cancer Treatment

Proteolysis-targeting chimeras (PROTACs) are molecules that selectively degrade a protein of interest (POI). The incorporation of ligands that recruit mouse double minute 2 (MDM2) into PROTACs, forming the so-called MDM2-based PROTACs, has shown promise in cancer treatment due to its dual mechanism...

Descripción completa

Detalles Bibliográficos
Autores principales: Vicente, André T. S., Salvador, Jorge A. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9570454/
https://www.ncbi.nlm.nih.gov/pubmed/36232374
http://dx.doi.org/10.3390/ijms231911068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9570454/
https://www.ncbi.nlm.nih.gov/pubmed/36232374
http://dx.doi.org/10.3390/ijms231911068

Ejemplares similares